Peripheral neuropathy - Treatment - NHS
This could include: Heart rate assessment at 4-8 weeks after initiation or dose escalation Periodic electrocardiography if arrhythmias are suspected Patient self-monitoring of pulse if symptomatic palpitations occur Evaluation of heart rate control in patients with atrial fibrillation When evaluating tachycardia in patients on GLP-1 therapy, clinicians should assess for other potential causes, including dehydration (especially from GI side effects), anemia, hyperthyroidism, stimulant use, infection, or other medications
Recomposition preserves the structural integrity of the body, including the face and other areas prone to volume loss, because lean muscle tissue signals the body to maintain protein synthesis and tissue repair rather than breaking down structural compartments for fuel
Therefore, the amount of copper absorbed by the intestine and retained in the body must be regulated to prevent accumulation of excess copperwhich is toxic
Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively
